To validate whether SMAD3 down-regulation was required for RAB26 silence-mediated anti-cancer effect on NSCLC, we additionally overexpressed SMAD3 in RAB26-silenced A549 cells to observe the changes in malignant processes. This evidence concerns the gene SMAD3 and cancer.